Deferoxamine: Clinical Trials

9 trials of Deferoxamine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 unknown, 1 not yet recruiting, 1 recruiting. 9 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 39Completed 5, Unknown 2, Not yet recruiting 1, Recruiting 1
Phase 24Completed 2, Not yet recruiting 1, Unknown 1

Follow Deferoxamine: new trials by email Literature Review of Deferoxamine trials Research Report on Deferoxamine

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Synergistic Minimally Invasive Surgery and Deferoxamine in ICH
Minimally Invasive surgery (MIS), Deferoxamine, Standard Medical Care (SMD) - Intracerebral Hemorrhage, ICH - Intracerebral Hemorrhage
Phase 2 / Phase 3Not yet recruitingUniversity of Illinois at Chicago2402026-03-012025-10-10
The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL
Colchicine 0.5 mg, Deferoxamine Mesylate, Control (Standard treatment) - Intracerebral Hemorrhage, Spontaneous Intracerebral Hemorrhage
Phase 3RecruitingThe George Institute20002025-02-272026-07-08
Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia
Tocilizumab Injection, Deferoxamine - COVID19, Intensive Care Unit
Phase 3UnknownAbderrahmane Mami Hospital2602020-09-042020-08-27
Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia
Omega 3, Nigella Sativa Oil, Hydroxyurea - Iron Overload, Oxidative Stress
Phase 2 / Phase 3CompletedBeni-Suef University3502019-11-012021-01-27
Evaluate the Efficacy and Safety of Irochel for the Management of Iron Overload in Thalassemia Patients in Comparison With Deferoxamine
Irochel, Deferoxamine - Iron Overload Due to Repeated Red Blood Cell Transfusions, Thalassemia Majors (Beta-Thalassemia Major)
Phase 3CompletedHamdard University1322019-02-112026-08-25
Amlodipine for Myocardial Iron in Thalassemia
Standard Chelation, Amlodipine - Thalassemia
Phase 2 / Phase 3CompletedAga Khan University202014-02-012017-06-29
Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload
DFP (ferriprox) and deferasirox (ICL 670), DFP, DFO - Beta-thalassemia Major, Sickle Cell Disease
Phase 2 / Phase 3UnknownAin Shams University602012-02-012012-02-06
Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions
ICL670, deferoxamine - Beta-Thalassemia
Phase 3CompletedNovartis Pharmaceuticals5952003-05-012012-04-19
Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients
Deferiprone (L1), Desferrioxamine - Hemochromatosis
Phase 3CompletedLipomed952002-01-012012-11-19

Conditions studied

Iron Overload (4)  ·  beta-Thalassemia (4)  ·  Thalassemia (3)  ·  Cerebral Hemorrhage (2)  ·  Anemia, Sickle Cell (1)  ·  COVID-19 (1)  ·  Hemochromatosis (1)  ·  Hemosiderosis (1)  ·  Stroke (1)

Sponsors

Abderrahmane Mami Hospital (1)  ·  Aga Khan University (1)  ·  Ain Shams University (1)  ·  Beni-Suef University (1)  ·  Hamdard University (1)  ·  Lipomed (1)  ·  Novartis Pharmaceuticals (1)  ·  The George Institute (1)  ·  University of Illinois at Chicago (1)

Countries

Egypt (3)  ·  Pakistan (2)  ·  United States (2)  ·  Australia (1)  ·  China (1)  ·  Saudi Arabia (1)  ·  Tunisia (1)  ·  Turkey (Türkiye) (1)

Top investigators

Ahmed F Mahmoud Hussein, MS.c (1)  ·  Amal M El-Beshlawy, Prof. Dr. (1)  ·  Babar Hasan (1)  ·  Gursant S. Atwal, MD (1)  ·  Javed Iqbal, MBBS (1)  ·  Mohsen S. Elalfy, professour (1)  ·  Yesim Aydinok, Prof. Dr. (1)

Results publications

PMID 37975597, PMID 17951527, PMID 18055982, PMID 18351337, PMID 22180427, PMID 25492271, PMID 25600572